Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-01613 |
Periostin/OSF-2 Protein, Mouse, Recombinant (His)
A630052E07Rik,OSF-2,Osf2,PLF,AI747096,peri,PN,perio... |
Mouse | HEK293 Cells |
Periostin/OSF-2 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 89 kDa and the accession number is Q62009-2. | |||
TMPK-01478 |
HLA-A*02:01&B2M&AFP (PLFQVPEPV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
AFP,FETA,Alpha-feto,HPAFP,Alpha-1-fetoprotein,MHC,Alpha-feto... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01521 |
HLA-A*02:01&B2M&AFP (PLFQVPEPV) Monomer Protein, Human, MHC (His & Avi)
MHC,Alpha-feto,AFPD,Alpha-1-fetoprotein,Alpha-fetoprotein,FE... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01520 |
HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer Protein, Human, MHC (His & Avi)
Alpha-1-fetoprotein,AFP,HPAFP,FETA,AFPD,MHC,Alpha-fetoprotei... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. |